{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:01:35Z","timestamp":1780326095931,"version":"3.54.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["437660"],"award-info":[{"award-number":["437660"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007202","name":"Gouvernement du Canada | Instituts de Recherche en Sant\u00e9 du Canada | CIHR Skin Research Training Centre","doi-asserted-by":"publisher","award":["408132"],"award-info":[{"award-number":["408132"]}],"id":[{"id":"10.13039\/501100007202","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1038\/s41416-026-03393-2","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:36:10Z","timestamp":1775579770000},"page":"1820-1829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potency and safety of novel [225Ac]Ac-labeled pertuzumab-PEGylated emtansine drug conjugate against HER2-positive breast cancer"],"prefix":"10.1038","volume":"134","author":[{"given":"Jessica","family":"Pougoue Ketchemen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissar","family":"Monzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice Ngoh","family":"Njotu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Babeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjong Florence","family":"Tikum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Nwangele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Henning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Futela","family":"Ngong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Doroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-6872","authenticated-orcid":false,"given":"Humphrey","family":"Fonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"3393_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41416-023-02272-4","volume":"129","author":"JP Ketchemen","year":"2023","unstructured":"Ketchemen JP, Babeker H, Tikum AF, Nambisan AK, Njotu FN, Nwangele E, et al. Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics. Br J Cancer. 2023;129:153\u201362.","journal-title":"Br J Cancer"},{"key":"3393_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CE.S217848","volume":"14","author":"K Ishii","year":"2019","unstructured":"Ishii K, Morii N, Yamashiro H. Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy. Core Evid. 2019;14:51\u201370.","journal-title":"Core Evid"},{"key":"3393_CR3","doi-asserted-by":"crossref","unstructured":"Pougoue Ketchemen J, Njotu FN, Babeker H, Ahenkorah S, Tikum AF, Nwangele E, et al. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2070\u201380.","DOI":"10.1007\/s00259-024-06648-3"},{"key":"3393_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-023-00849-9","volume":"21","author":"A Marra","year":"2024","unstructured":"Marra A, Chandarlapaty S, Modi S. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives. Nat Rev Clin Oncol. 2024;21:185\u2013202.","journal-title":"Nat Rev Clin Oncol"},{"key":"3393_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab Emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391.","journal-title":"N Engl J Med"},{"key":"3393_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"3393_CR7","doi-asserted-by":"crossref","unstructured":"Abelman RO, Medford A, Spring L, Bardia A. Antibody-drug conjugates in breast cancer: spotlight on HER2. Cancer J. 2022;28:423\u20138.","DOI":"10.1097\/PPO.0000000000000634"},{"key":"3393_CR8","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68:5878\u201387.","journal-title":"Cancer Res"},{"key":"3393_CR9","doi-asserted-by":"crossref","unstructured":"Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature.487:505\u20139.","DOI":"10.1038\/nature11249"},{"key":"3393_CR10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature05474","volume":"445","author":"NV Sergina","year":"2007","unstructured":"Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437\u201341.","journal-title":"Nature"},{"key":"3393_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463\u201375.","journal-title":"Nat Rev Cancer"},{"key":"3393_CR12","doi-asserted-by":"crossref","unstructured":"Campbell MR, Amin D, Moasser MM HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 16: 1373\u201383.","DOI":"10.1158\/1078-0432.CCR-09-1218"},{"key":"3393_CR13","doi-asserted-by":"crossref","unstructured":"Choi BK, Fan X, Deng H, Zhang N, An Z ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Med. 1:28\u201338.","DOI":"10.1002\/cam4.10"},{"key":"3393_CR14","first-page":"1813","volume":"10","author":"M Alimandi","year":"1995","unstructured":"Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995;10:1813\u201321.","journal-title":"Oncogene"},{"key":"3393_CR15","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1073\/pnas.1537685100","volume":"100","author":"T Holbro","year":"2003","unstructured":"Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, et al. The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003;100:8933\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3393_CR16","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.3390\/cancers15133419","volume":"15","author":"J Karlsson","year":"2023","unstructured":"Karlsson J, Hagemann UB, Cruciani V, Schatz CA, Grant D, Ellingsen C, et al. Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-positive breast cancer bone metastasis model. Cancers. 2023;15:3419.","journal-title":"Cancers"},{"key":"3393_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","volume":"33","author":"Y-S Kim","year":"2012","unstructured":"Kim Y-S, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol. 2012;33:573\u201390.","journal-title":"Tumor Biol"},{"key":"3393_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","volume":"109","author":"S Aghevlian","year":"2017","unstructured":"Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102\u201318.","journal-title":"Adv Drug Deliv Rev"},{"key":"3393_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2967\/jnumed.108.058651","volume":"51","author":"G Sgouros","year":"2010","unstructured":"Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of \u03b1-Particle Emitters for Targeted Radionuclide Therapy. J Nucl Med. 2010;51:311\u201328.","journal-title":"J Nucl Med"},{"key":"3393_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.brachy.2023.06.228","volume":"22","author":"F Mourtada","year":"2023","unstructured":"Mourtada F, Tomiyoshi K, Sims-Mourtada J, Mukai-Sasaki Y, Yagihashi T, Namiki Y, et al. Actinium-225 targeted agents: where are we now?. Brachytherapy. 2023;22:697\u2013708.","journal-title":"Brachytherapy"},{"key":"3393_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1021\/acs.bioconjchem.2c00190","volume":"33","author":"KJ Kadassery","year":"2022","unstructured":"Kadassery KJ, King AP, Fayn S, Baidoo KE, MacMillan SN, Escorcia FE, et al. H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. Bioconjug Chem. 2022;33:1222\u201331.","journal-title":"Bioconjug Chem"},{"key":"3393_CR22","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.3390\/cancers13081974","volume":"13","author":"F Reissig","year":"2021","unstructured":"Reissig F, Bauer D, Zarschler K, Novy Z, Bendova K, Ludik M-C, et al. Towards Targeted Alpha Therapy with Actinium-225: Chelators for mild condition radiolabeling and targeting PSMA\u2014a proof of concept study. Cancers. 2021;13:1974.","journal-title":"Cancers"},{"key":"3393_CR23","first-page":"336","volume":"33","author":"NA Thiele","year":"2018","unstructured":"Thiele NA, Wilson JJ. Actinium-225 for Targeted \u03b1 Therapy: Coordination chemistry and current chelation approaches. Cancer Biother Radiopharm. 2018;33:336\u201348.","journal-title":"Cancer Biother Radiopharm"},{"key":"3393_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The Impact of PEGylation on Biological Therapies. BioDrugs. 2008;22:315\u201329.","journal-title":"BioDrugs"},{"key":"3393_CR25","doi-asserted-by":"publisher","first-page":"14712","DOI":"10.1002\/anie.201709532","volume":"56","author":"NA Thiele","year":"2017","unstructured":"Thiele NA, Brown V, Kelly JM, Amor-Coarasa A, Jermilova U, Macmillan SN, et al. An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angew Chem Int Ed. 2017;56:14712\u20137.","journal-title":"Angew Chem Int Ed"},{"key":"3393_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/BF00300234","volume":"24","author":"MM Tomayko","year":"1989","unstructured":"Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3393_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2967\/jnumed.123.266204","volume":"65","author":"AF Tikum","year":"2024","unstructured":"Tikum AF, Ketchemen JP, Doroudi A, Nambisan AK, Babeker H, Njotu FN, et al. Effectiveness of 225Ac-Labeled Anti-EGFR radioimmunoconjugate in EGFR-positive Kirsten rat sarcoma viral oncogene and BRAF mutant colorectal cancer models. J Nucl Med. 2024;65:402\u20138.","journal-title":"J Nucl Med"},{"key":"3393_CR28","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.7150\/thno.75336","volume":"12","author":"S Ahenkorah","year":"2022","unstructured":"Ahenkorah S, Murce E, Cawthorne C, Ketchemen JP, Deroose CM, Cardinaels T, et al. 3p-C-NETA: A versatile and effective chelator for development of Al18F-labeled and therapeutic radiopharmaceuticals. Theranostics. 2022;12:5971\u201385.","journal-title":"Theranostics"},{"key":"3393_CR29","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA: A Cancer J Clin"},{"key":"3393_CR30","doi-asserted-by":"publisher","first-page":"116522","DOI":"10.1016\/j.biopha.2024.116522","volume":"174","author":"J Yu","year":"2024","unstructured":"Yu J, Li M, Liu X, Wu S, Li R, Jiang Y, et al. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions. Biomed Pharmacother. 2024;174:116522.","journal-title":"Biomed Pharmacother"},{"key":"3393_CR31","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24:9674.","journal-title":"Int J Mol Sci"},{"key":"3393_CR32","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/cancers15041278","volume":"15","author":"RO Abelman","year":"2023","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of resistance to antibody\u2013drug conjugates. Cancers. 2023;15:1278.","journal-title":"Cancers"},{"key":"3393_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118\u201345.","journal-title":"J Clin Oncol"},{"key":"3393_CR34","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1158\/1078-0432.CCR-06-1304","volume":"13","author":"LN Harris","year":"2007","unstructured":"Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007;13:1198\u2013207.","journal-title":"Clin Cancer Res"},{"key":"3393_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","volume":"191","author":"G Lewis Phillips","year":"2022","unstructured":"Lewis Phillips G, Guo J, Kiefer JR, Proctor W, Bumbaca Yadav D, Dybdal N, et al. Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Res Treat. 2022;191:303\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"3393_CR36","first-page":"13","volume":"1","author":"N Mohan","year":"2018","unstructured":"Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. Antib Ther. 2018;1:13\u20137.","journal-title":"Antib Ther"},{"key":"3393_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"N Dempsey","year":"2021","unstructured":"Dempsey N, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188:21\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"3393_CR38","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:23\u201339.","journal-title":"Breast Cancer Res Treat"},{"key":"3393_CR39","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1021\/acs.molpharmaceut.9b00542","volume":"16","author":"VR Solomon","year":"2019","unstructured":"Solomon VR, Alizadeh E, Bernhard W, Hartimath SV, Hill W, Chekol R, et al. 111In- and 225Ac-labeled cixutumumab for imaging and \u03b1-particle radiotherapy of IGF-1R positive triple-negative breast cancer. Mol Pharmac. 2019;16:4807\u201316.","journal-title":"Mol Pharmac"},{"key":"3393_CR40","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1007\/s00259-021-05315-1","volume":"48","author":"NK Tafreshi","year":"2021","unstructured":"Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, et al. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021;48:3408\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3393_CR41","doi-asserted-by":"crossref","unstructured":"Ma J, Li L, Liao T, Gong W, Zhang C Efficacy and Safety of 225Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.796657"},{"key":"3393_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"3393_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.nucmedbio.2005.12.006","volume":"33","author":"G Akabani","year":"2006","unstructured":"Akabani G, Carlin S, Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33:333\u201347.","journal-title":"Nucl Med Biol"},{"key":"3393_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.2967\/jnumed.122.264071","volume":"64","author":"Y Feng","year":"2023","unstructured":"Feng Y, Meshaw R, Zhao X-G, Jannetti S, Vaidyanathan G, Zalutsky MR. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose211At-Labeled Anti-HER2 Single-Domain Antibody Fragment. J Nucl Med. 2023;64:124\u201330.","journal-title":"J Nucl Med"},{"key":"3393_CR45","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ijrobp.2010.08.038","volume":"79","author":"H Heyerdahl","year":"2011","unstructured":"Heyerdahl H, Krogh C, Borreb\u00e6k J, Larsen \u00c5, Dahle J. Treatment of HER2-Expressing Breast Cancer and Ovarian Cancer Cells With Alpha Particle-Emitting 227Th-Trastuzumab. Int J Radiat Oncol*Biol*Phys. 2011;79:563\u201370.","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"3393_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109805","volume":"186","author":"V Salvestrini","year":"2023","unstructured":"Salvestrini V, Kim K, Caini S, Alkner S, Ekholm M, Skytta T, et al. Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis. Radiother Oncol. 2023;186:109805.","journal-title":"Radiother Oncol"},{"key":"3393_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.216024","volume":"554","author":"L Gandullo-S\u00e1nchez","year":"2023","unstructured":"Gandullo-S\u00e1nchez L, Pandiella A. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023;554:216024.","journal-title":"Cancer Lett"},{"key":"3393_CR48","doi-asserted-by":"crossref","unstructured":"Tobin SJ, Wakefield DL, Jones V, Liu X, Schmolze D, Jovanovi\u0107-Talisman T Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. Sci Rep. 2018;8:15154.","DOI":"10.1038\/s41598-018-33225-0"},{"key":"3393_CR49","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","volume":"58","author":"C Kratochwil","year":"2017","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with (225)Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. J Nucl Med. 2017;58:1624\u201331.","journal-title":"J Nucl Med"},{"key":"3393_CR50","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/ph12040155","volume":"12","author":"K Wickstroem","year":"2019","unstructured":"Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, et al. Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model. Pharmaceuticals. 2019;12:155.","journal-title":"Pharmaceuticals"},{"key":"3393_CR51","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1158\/1541-7786.MCR-21-0545","volume":"20","author":"D Casadevall","year":"2022","unstructured":"Casadevall D, Hern\u00e1ndez-Prat A, Garc\u00eda-Alonso S, Arp\u00ed-Lluci\u00e0 O, Men\u00e9ndez S, Qin M, et al. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Mol Cancer Res. 2022;20:1108\u201321.","journal-title":"Mol Cancer Res"},{"key":"3393_CR52","doi-asserted-by":"publisher","first-page":"e42345","DOI":"10.1371\/journal.pone.0042345","volume":"7","author":"H Heyerdahl","year":"2012","unstructured":"Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab. PLoS ONE. 2012;7:e42345.","journal-title":"PLoS ONE"},{"key":"3393_CR53","doi-asserted-by":"crossref","unstructured":"Weisser NE, Sanches M, Escobar-Cabrera E, O\u2019Toole J, Whalen E, Chan PWY, et al. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity. Nat Commun. 2023;14:1394.","DOI":"10.1038\/s41467-023-37029-3"},{"key":"3393_CR54","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/OTT.S357326","volume":"15","author":"X Hui","year":"2022","unstructured":"Hui X, Yuan C, Cao W, Ge W, Zhang D, Dan M, et al. An innovative site-specific anti-HER2 antibody-drug conjugate with high homogeneity and improved therapeutic Index. OncoTargets Ther. 2022;15:331\u201343.","journal-title":"OncoTargets Ther"},{"key":"3393_CR55","doi-asserted-by":"publisher","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"H Song","year":"2009","unstructured":"Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with \u03b1-Particle Emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69:8941\u20138.","journal-title":"Cancer Res"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03393-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03393-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:03:59Z","timestamp":1780322639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03393-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,20]]}},"alternative-id":["3393"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03393-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal protocols were approved by the University of Saskatchewan Animal Care Committee (UACC) (protocol # 20220021) and the Animal Protection Committee of Universit\u00e9 Laval (CPAUL) (protocol # 2024-1614). Animals were fed\n                      ad libitum\n                      with food (Lab Diet, St. Louis, MO) and water and were maintained at 12\u2009h light and 12\u2009h dark cycles, in a humidity-controlled vivarium. \u00a0Three days to\u00a0one week of acclimatisation was required before using the animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}